Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 8/20 | 0.35 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.35 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.35 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.35 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.35 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.35 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14589071 | 1.00 | ALDH1A1 (0.44) | ALDH1A1HSD11B1HRH3CHRNB2CHRNB4 | |
| SCHEMBL26957504 | 1.00 | ALDH1A1 (0.44) | ALDH1A1HSD11B1HRH3CHRNB2CHRNB4 | |
| SCHEMBL26957962 | 1.00 | ALDH1A1 (0.44) | ALDH1A1HSD11B1HRH3CHRNB2CHRNB4 | |
| SCHEMBL27117248 | 0.97 | ALDH1A1 (0.41) | ALDH1A1HSD11B1HRH3CHRNB2CHRNB4 | |
| SCHEMBL21440591 | 0.97 | ALDH1A1 (0.41) | ALDH1A1HSD11B1HRH3CHRNB2CHRNB4 | |
| SCHEMBL18313245 | 0.97 | ALDH1A1 (0.41) | ALDH1A1HSD11B1HRH3CHRNB2CHRNB4 | |
| SCHEMBL12620808 | 0.97 | ALDH1A1 (0.41) | ALDH1A1HSD11B1HRH3CHRNB2CHRNB4 | |
| SCHEMBL19343100 | 0.97 | ALDH1A1 (0.41) | ALDH1A1HSD11B1HRH3CHRNB2CHRNB4 | |
| SCHEMBL14407323 | 0.97 | ALDH1A1 (0.41) | ALDH1A1HSD11B1HRH3CHRNB2CHRNB4 | |
| SCHEMBL13201847 | 0.93 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 209 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11795177-B2 | Substituted quinoline analogs as aldehyde dehydrogenase 1A1 (ALDH1A1) inhibitors | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2023-10-24 | — | — | US | disclosed |
| US-20230203048-A1 | SPIROPYRROLIDINE DERIVED ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2023-06-29 | — | — | US | disclosed |
| US-20230203048-A1 | SPIROPYRROLIDINE DERIVED ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2023-06-29 | — | — | US | disclosed |
| US-20230112485-A1 | THERAPEUTIC COMPOUNDS | GENENTECH, INC. (US) | 2023-04-13 | — | — | US | disclosed |
| US-20230109839-A1 | THERAPEUTIC AGENT FOR TAUOPATHIES | Sumitomo Pharma Co., Ltd. (JP) | 2023-04-13 | — | — | US | disclosed |
| EP-4159736-A1 | NOVEL TRICYCLIC AROMATIC HETEROCYCLIC COMPOUND AND PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION AND USE THEREOF | Shanghai Longwood Biopharmaceuticals Co., Ltd. (CN) | 2023-04-05 | — | — | EP | disclosed |
| WO-2023018648-A1 | PHENOL DERIVATIVES FOR USE IN THE MODULATION OF BRM | GENENTECH, INC. (US) | 2023-02-16 | — | — | WO | disclosed |
| WO-2022263548-A1 | 3-SUBSTITUTED 1H-PYRROLO[2,3-B]PYRIDINE AS GRK5 MODULATORS | LEAD DISCOVERY CENTER GMBH (DE) | 2022-12-22 | — | — | WO | disclosed |
| EP-4104901-A1 | 3-SUBSTITUTED 1H-PYRROLO[2,3-B]PYRIDINE AS GRK5 MODULATORS | Lead Discovery Center GmbH (DE) | 2022-12-21 | — | — | EP | disclosed |
| US-20220145339-A1 | METHOD FOR PREPARATION OF PRIMARY AMINE COMPOUNDS | MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2022-05-12 | — | — | US | disclosed |
| US-20070213359-A1 | BICYCLIC-NITROGEN COMPOUNDS AS MODULATORS OF GHRELIN RECEPTOR AND USES THEREOF | ACADIA PHARMACEUTICALS INC. (US) | 2007-09-13 | — | — | US | disclosed |
| US-20070213356-A1 | Nitrogen-Containing Heterocyclyl Substituted Imidazoquinolines and Imidazonaphthyridines | 3M INNOVATIVE PROPERTIES COMPANY | 2007-09-13 | — | — | US | disclosed |
| WO-2007093366-A1 | NOVEL AMINOALCOHOL-SUBSTITUTED ARYLDIHYDROISOQUINOLINONES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS | SANOFI-AVENTIS (DE) | 2007-08-23 | — | — | WO | disclosed |
| US-20070191395-A1 | Heterocyclic compounds having antifungal activity | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-08-16 | — | — | US | disclosed |
| US-20070191395-A1 | Heterocyclic compounds having antifungal activity | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-08-16 | — | — | US | disclosed |
| EP-1790641-A1 | TRIAZOLE DERIVATIVE OR SALT THEREOF | Astellas Pharma Inc. (JP) | 2007-05-30 | — | — | EP | disclosed |
| EP-0740657-B1 | 4-ARYLISOINDOLE ANALGESICS | ORTHO PHARMA CORP (US) | 2002-03-06 | — | — | EP | disclosed |
| EP-0740657-A1 | 4-ARYLISOINDOLE ANALGESICS | ORTHO PHARMACEUTICAL CORPORATION (US) | 1996-11-06 | — | — | EP | disclosed |
| US-5543530-A | 4-arylisoindole analgesics | ORTHO PHARMACEUTICAL CORPORATION (US) | 1996-08-06 | — | — | US | disclosed |
| WO-1995017384-A1 | 4-ARYLISOINDOLE ANALGESICS | ORTHO PHARMACEUTICAL CORPORATION (US) | 1995-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230203048-A1 | SPIROPYRROLIDINE DERIVED ANTIVIRAL AGENTS | ACE, ACE2, PKD1 | ALDH1A1 319/4885HSD11B1 35/4885HRH3 4059/4885 |
| US-20230112485-A1 | THERAPEUTIC COMPOUNDS | BRDT, BRPF3, SNRPE | ALDH1A1 4242/4885HSD11B1 3658/4885HRH3 2384/4885 |
| US-20070213356-A1 | Nitrogen-Containing Heterocyclyl Substituted Imidazoquinolines and Imidazonaphthyridines | IL2, IFNG, IRF3 | ALDH1A1 2879/4885HSD11B1 4793/4885HRH3 338/4885 |
| US-20230109839-A1 | THERAPEUTIC AGENT FOR TAUOPATHIES | MAPT, PSEN1, PSEN2 | ALDH1A1 4081/4885HSD11B1 2890/4885HRH3 3182/4885 |
| US-20070213359-A1 | BICYCLIC-NITROGEN COMPOUNDS AS MODULATORS OF GHRELIN RECEPTOR AND USES THEREOF | GIPR, GHSR, GHRHR | ALDH1A1 2963/4885HSD11B1 1392/4885HRH3 527/4885 |
| US-20070191395-A1 | Heterocyclic compounds having antifungal activity | ERG28, MANBA, MAN2B1 | ALDH1A1 1357/4885HSD11B1 446/4885HRH3 3568/4885 |
| US-11795177-B2 | Substituted quinoline analogs as aldehyde dehydrogenase 1A1 (ALDH1A1) inhibitors | ALDH1A1, ALDH1A2, ALDH1B1 | ALDH1A1 1/4885HSD11B1 371/4885HRH3 1749/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.